Klaria Interim Report Q3 2021
Summary of the interim report
Promising quarter with registration applications and preparations for additional clinical studies
THIRD QUARTER OF 2021
- Net sales amounted to 0.0 MSEK (0.0 MSEK)
- Other income amounted to 0.0 MSEK (3.4 MSEK)
- R&D costs for the period amounted to 12.5 MSEK (13.6 MSEK)
- Profit after tax amounted to -15.2 MSEK (-13.3 MSEK)
- Earnings per share for the quarter amounted to -0.29 SEK (-0.28 SEK)
- Cash flow from operating activities amounted to -13.7 MSEK (-12.2 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 25.9 MSEK (19.3 MSEK)
- Equity as of September 30 amounted to 95.2 MSEK (104.5 MSEK)
- The Pure Jamaican company group and Klaria has signed agreements on R&D and commercialization in Latin America and the Caribbean.
- Cannabis Delivery Sciences has signed an agreement with Hemply Balance for commercialization of Alginate Films with CBD in Europe.
THE PERIOD JANUARY-SEPTEMBER 2021
- Net sales amounted to 0.0 MSEK (0.0 MSEK)
- Other income amounted to 31.3 MSEK (6.0 MSEK)
- R&D costs for the period amounted to 35.4 MSEK (30.8 MSEK)
- Profit after tax amounted to -14.4 MSEK (-34.4 MSEK)
- Earnings per share for the period amounted to -0.28 SEK (-0.83 SEK)
- Cash flow from operating activities amounted to -10.2 MSEK (-25.2 MSEK)
- An up-front payment of 30.5 MSEK was received from Imbrium Therapuetics in connection with signing an option agreement regarding the market rights to the drug candidate Adrenalin Alginate film for treatment of severe allergic reactions.
- Klaria has received a third payment of approximately 2.2 MSEK from the EU's Horizon 2020 program for the development of Sumatriptan Alginate Film.
- Klaria's combination patent for alginate film with Sumatriptan has been approved in the USA.
- Klaria has signed a new financing agreement of 50 MSEK.